Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers

Amedisys Shares Decline After Company Lowers 2011 Forecast

Amedisys Inc. plunged the most in about 16 months after the provider of at-home health care lowered its full-year earnings forecast and said the chief operating officer will leave.

Amedisys dropped 23 percent to $10.06 at the close in New York, the biggest single-day decline since July 2010. Full-year profit, excluding certain items, will be $1.90 to $2 a share, the Baton Rouge, Louisiana-based company said today in a statement. In August, Amedisys said it expected $2.20 to $2.40 a share.

Because of an anticipated cut in Medicare payments next year and a “disappointing operating performance,” Amedisys said it has identified about 50 care centers that will be sold, closed or reduced. The company reported a third-quarter net loss of $423.7 million, or $14.73 a share, hurt by a goodwill and impairment charge.

The departure of Mike Snow, the chief operating officer, “is a big blow to the company,” said Arthur Henderson, an analyst with Jefferies & Co. in Nashville, Tennessee, in a research note. “Amedisys’ management shake-up, its weak operating and financial trajectory, and the highly uncertain home nursing reimbursement environment combine for a stormy near-term outlook.”

Revenue declined 7.4 percent to $374.9 million in the quarter, Amedisys said. A year earlier, the company had net income of $21.6 million, or 76 cents a share.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.